Company intelligence / Profile preview
JCR Pharmaceuticals
- Ownership
- Public · 4552
- Employees
- ~750
- Development stage
- Commercial
Overview
JCR has achieved commercial approval for several first-in-class therapies in Japan including IZCARGO® for Hunter syndrome and TEMCELL® HS Inj. for acute graft-versus-host disease. Its pipeline is focused on rare genetic disorders with multiple global Phase III programs ongoing or recently completed.
- Therapeutic areas
- EndocrinologyRare DiseasesImmunologyNephrology
- Modalities
- Enzyme replacement therapyRecombinant proteinCell therapyRegenerative medical productSmall molecule (biosimilars)
- Industry
- Biotech
Drug pipeline
24 assets23 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $376.4M
- Total revenue
- $254.9M
- Enterprise value
- $712.9M
Beyond the preview
Go deeper on JCR Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCR Pharmaceuticals.